Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Sirna's RNAi Work Lands $250M Deal With Allergan

Sep. 30, 2005

By Jennifer Boggs

Genomic Health's IPO Adds $60M For Breast Cancer Test

Sep. 30, 2005

By Jennifer Boggs

Insmed's Growth Hormone Approvable; 'Issues' Remain

Sep. 29, 2005

By Jennifer Boggs

Scynexis, Merial Enter Potential $150M Animal Health Partnership

Sep. 29, 2005

By Jennifer Boggs

Scynexis, Merial Enter Potential $150M Animal Health Partnership

Sep. 29, 2005

By Jennifer Boggs

Insmed's Growth Hormone Approvable; 'Issues' Remain

Sep. 29, 2005

By Jennifer Boggs

Banking On MyoCell, Bioheart Gets Series D Round Of $19M

Sep. 28, 2005

By Jennifer Boggs

Sunesis Prices $42M IPO To Fuel Oncology Pipeline

Sep. 28, 2005

By Jennifer Boggs

Sunesis Prices $42M IPO To Fuel Oncology Pipeline

Sep. 28, 2005

By Jennifer Boggs

Banking On MyoCell, Bioheart Gets Series D Round Of $19M

Sep. 28, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 8, 2025
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
BioWorld
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...
GLP-1 receptor agonists continue their global victory tour
BioWorld
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
AI drives financings, approvals for APAC med-tech in 2024
BioWorld MedTech
AI pulled in major financings and approvals for Asia med-techs in 2024 as Asia Pacific countries played to individual strengths to maximize AI’s applications in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.